within Pharmacolibrary.Drugs.ATC.L;

model L01EL03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.17,
    Cl             = 0.26166666666666666,
    adminDuration  = 600,
    adminMass      = 0.16,
    adminCount     = 1,
    Vd             = 0.128,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 25.2
  );

  annotation(Documentation(
    info ="<html><body><p>Zanubrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies such as mantle cell lymphoma, Waldenström's macroglobulinemia, and chronic lymphocytic leukemia. It has received FDA approval for certain hematological cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for patients with B-cell malignancies following oral administration of zanubrutinib at a dose of 160 mg, twice daily. Data primarily from adult patients.</p><h4>References</h4><ol><li><p>Mu, S, et al., &amp; Sahasranaman, S (2020). Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton&#x27;s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. <i>Cancer chemotherapy and pharmacology</i> 85(2) 391–399. DOI:<a href=&quot;https://doi.org/10.1007/s00280-019-04015-w&quot;>10.1007/s00280-019-04015-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31875923/&quot;>https://pubmed.ncbi.nlm.nih.gov/31875923</a></p></li><li><p>Chen, L, et al., &amp; Chen, W (2022). Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib. <i>Frontiers in pharmacology</i> 13 960186–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2022.960186&quot;>10.3389/fphar.2022.960186</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36299883/&quot;>https://pubmed.ncbi.nlm.nih.gov/36299883</a></p></li><li><p>Zhu, YL, et al., &amp; Zhang, HW (2023). A rapid and sensitive UPLC-MS/MS method for the determination of zanubrutinib in beagle plasma and its application in pharmacokinetics. <i>Biomedical chromatography : BMC</i> 37(1) e5504–None. DOI:<a href=&quot;https://doi.org/10.1002/bmc.5504&quot;>10.1002/bmc.5504</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36094354/&quot;>https://pubmed.ncbi.nlm.nih.gov/36094354</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EL03;
